[go: up one dir, main page]

MX2022001069A - Composiciones y metodos para el tratamiento de la presbicia. - Google Patents

Composiciones y metodos para el tratamiento de la presbicia.

Info

Publication number
MX2022001069A
MX2022001069A MX2022001069A MX2022001069A MX2022001069A MX 2022001069 A MX2022001069 A MX 2022001069A MX 2022001069 A MX2022001069 A MX 2022001069A MX 2022001069 A MX2022001069 A MX 2022001069A MX 2022001069 A MX2022001069 A MX 2022001069A
Authority
MX
Mexico
Prior art keywords
presbyopia
methods
treatment
ophthalmic compositions
compositions
Prior art date
Application number
MX2022001069A
Other languages
English (en)
Inventor
Michael R Robinson
Mohammed Dibas
Anuradha Gore
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX2022001069A publication Critical patent/MX2022001069A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona con composiciones oftálmicas tópicas que comprenden uno o más componentes activos. Los componentes activos en las composiciones oftálmicas tópicas incluyen, pero no se limitan a, carbacol, yoduro de fosfolina y sus sales farmacéuticamente aceptables. En la presente, también se describen métodos para el tratamiento de la presbicia, métodos para mejorar la visión de cerca en un sujeto con presbicia y métodos para reducir el diámetro de la pupila en un sujeto con presbicia usando las composiciones oftálmicas tópicas.
MX2022001069A 2019-07-26 2020-07-24 Composiciones y metodos para el tratamiento de la presbicia. MX2022001069A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962879296P 2019-07-26 2019-07-26
PCT/US2020/043534 WO2021021646A1 (en) 2019-07-26 2020-07-24 Compositions and methods for treatment of presbyopia

Publications (1)

Publication Number Publication Date
MX2022001069A true MX2022001069A (es) 2022-02-14

Family

ID=74229810

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001069A MX2022001069A (es) 2019-07-26 2020-07-24 Composiciones y metodos para el tratamiento de la presbicia.

Country Status (9)

Country Link
US (1) US20220273605A1 (es)
EP (1) EP4003246A4 (es)
JP (1) JP2022541854A (es)
KR (1) KR20220041151A (es)
CN (1) CN114269301A (es)
AU (1) AU2020323475A1 (es)
CA (1) CA3147107A1 (es)
MX (1) MX2022001069A (es)
WO (1) WO2021021646A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4153166A1 (en) 2020-05-18 2023-03-29 Vyluma Inc. Low-dose carbachol compositions and methods for treatment of night vision disturbance
WO2022249069A1 (en) * 2021-05-26 2022-12-01 Vyluma Inc. Low-dose carbachol ophthalmic compositions with cumulative effect
WO2023086878A1 (en) 2021-11-10 2023-05-19 Visus Therapeutics, Inc. Carbachol formulations to enhance anti-presbyopia effects
TW202333700A (zh) * 2021-12-16 2023-09-01 美商倫茨治療公司 用於治療眼病之組成物及方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4136177A (en) * 1977-01-31 1979-01-23 American Home Products Corp. Xanthan gum therapeutic compositions
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
WO2010125416A1 (en) * 2009-04-27 2010-11-04 Raouf Rekik Drug delivery to the anterior and posterior segments of the eye
US8299079B2 (en) * 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
US20100298335A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and Methods for Ameliorating or Reducing Presbyopia
US9089562B2 (en) * 2013-08-28 2015-07-28 Presbyopia Therapies Llc Compositions and methods for the treatment of presbyopia

Also Published As

Publication number Publication date
AU2020323475A1 (en) 2022-03-03
KR20220041151A (ko) 2022-03-31
JP2022541854A (ja) 2022-09-27
EP4003246A1 (en) 2022-06-01
US20220273605A1 (en) 2022-09-01
EP4003246A4 (en) 2023-08-16
WO2021021646A1 (en) 2021-02-04
CA3147107A1 (en) 2021-02-04
CN114269301A (zh) 2022-04-01

Similar Documents

Publication Publication Date Title
PH12020551766A1 (en) Use of pilocarpine hydrochloride for the treatment of ocular conditions
MX2022001069A (es) Composiciones y metodos para el tratamiento de la presbicia.
MX2023003124A (es) Composiciones farmaceuticas oftalmicas y usos que se relacionan a las mismas.
PH12021550882A1 (en) Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
AR121843A2 (es) Formulación oftálmica y método para mejorar la presbicia
WO2016172712A3 (en) Ophthalmic composition
HK1258588A1 (zh) 用於治療眼科疾病的化合物和製劑
RU2017144173A (ru) Конструкция линзы с центральной зоной лечения с высокой положительной оптической силой и способ предотвращения и/или замедления прогрессирования миопии
EA201300272A1 (ru) Применение фотоусиливающих агентов в ассоциации с рибофлавином, а также соответствующих офтальмологических композиций для перекрестного сшивания роговицы при лечении кератоконуса или других эктазийных расстройств роговицы
EA201301277A1 (ru) Композиции и способы лечения заболеваний сетчатки
NZ704247A (en) Compositions and treatment for eye diseases and disorders
EP4324454A3 (en) Cross-linking agents and associated methods
EP2778749A3 (en) Presbyopia lens with pupil size correction based on level of refractive error
EP4397375A3 (en) Isoxazoline parasiticide formulations and methods for treating blepharitis
ZA202108950B (en) Oxymetazoline compositions and methods for treating ocular disorders
IN2013DE03085A (es)
MX2022001062A (es) Peptidos para el tratamiento de degeneracion macular no exudativa y otros trastornos del ojo.
WO2023081830A3 (en) Compositions and treatments with nirogacestat
PH12021550372A1 (en) The use of alpha-2-adrenergic receptor agonists for improving vision
Mahadevan et al. Unique hard scleral lens post-LASIK ectasia fitting
EA202192183A1 (ru) Композиции, обладающие активностью удаления липофусцина из клеток сетчатки
EA201690903A1 (ru) Лечение глаукомы с использованием лаквинимода
EP2563350A4 (en) THERAPEUTIC REGIME AND METHOD FOR THE TREATMENT OR IMPROVEMENT OF VIEW DISORDERS ASSOCIATED WITH ENDOGENOUS RETINOID DEFICIENCY
PH12020550722A1 (en) Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye
MX2023002946A (es) Composiciones y metodos para tratar presbicia, hipermetropia, astigmatismo, estereopsis disminuida, y sensibilidad al contraste disminuida.